Market Intelligence, Clinical Progress, and High-Purity Reagents for Epithelial Carcinoma, Liquid Biopsy, Solid Tumor ADC & Bispecific Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EPCAM drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPCAM ECD-Fc Fusion Protein Human extracellular domain (Met1-Gln265), HEK293 expressed, Theoretical MW 55 kDa, High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified |
View EPCAM Products |
| Gene Delivery | EPCAM Promise-ORF Lentivirus Full-length human ORF (NM_002354) with native signal peptide, CMV promoter, Puromycin selection, for stable cell line generation |
View EPCAM Products |
| Benchmark Ab | Anti-EPCAM (Sequence of Catumaxomab) Recombinant rat/murine chimeric bispecific positive control, Sequence Verified |
View EPCAM Products |
| Validator | EPCAM siRNA Set Three target-specific siRNAs plus negative control, chemically modified for stability, Sequence Verified |
View EPCAM Products |
| Related Target: TROP2 | TACSTD2 (TROP2) Structurally related TACSTD family member, synergistic expression in epithelial malignancies |
View TACSTD2 Products |
| Related Target: CDH1 | CDH1 (E-cadherin) Direct adhesion partner, critical for epithelial-mesenchymal transition studies |
View CDH1 Products |
| Related Target: CD3E | CD3E Bispecific T-cell engager axis; essential for EpCAMxCD3 dual-targeting programs |
View CD3E Products |
| Related Target: EGFR | EGFR Co-expressed receptor in epithelial cancers for combination therapy |
View EGFR Products |
Critical Assay Challenges & Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Internalization Efficiency (ADC payload delivery) | EPCAM ECD-Fc with native glycosylation pattern preserves conformational epitopes; HEK293 expression ensures proper folding for internalization assay validation |
| Cross-species cyno/mouse toxicology eval | Human/Mouse/Cyno EPCAM ortholog proteins available with >95% purity, Sequence Verified for binding affinity comparisons |
| Soluble EPCAM (sEpCAM) interference in PK/PD | High-purity recombinant sEpCAM standard (ECD only) for assay calibration and competitive binding studies |
| Epitope binning (Domain specificity) | Domain-truncation mutant proteins (EGF-like domain deletions) available for precise epitope mapping |
| False Positives / Off-target binding | Validated siRNA included for specificity checks; Lentivirus-generated stable knockdown cell lines as negative controls |
| Precise Affinity Tuning (Toxicity Avoidance) | Homolog panel proteins strictly verified by mass spec for rigorous SPR/BLI |
| Subfamily Counter-screening (TROP2) | TROP2 (TACSTD2) homolog protein; Sequence Verified; High Purity (>95%) for selectivity panels |
Live EPCAM/CD326 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EPCAM therapeutics is intensifying, with major players shifting focus from traditional murine monoclonals (e.g., edrecolomab) to next-generation bispecifics, ADCs, and CAR-T cells. As first-generation therapies like catumaxomab established proof-of-concept for malignant ascites, the next wave of R&D is targeting solid tumor penetration and reduced immunogenicity through humanized formats. Key strategies include conditional activation (masked ADCs, site-specific conjugation) and precise affinity tuning to widen the therapeutic window, mitigating on-target, off-tumor toxicities. The emergence of circulating tumor cell (CTC) isolation technologies has further expanded EPCAM's utility from therapeutics to companion diagnostics, driving demand for high-affinity reagents capable of capturing rare epithelial cells from liquid biopsies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Emerging Biotechs, ADC Specialized CROs, Viventia/Sesen Bio, Various Biopharma | Colorectal, Gastric, Bladder, Ovarian, GI Solid Tumors | Internalization Assay (Need high-purity ECD-Fc for pH-sensitive dye conjugation) |
| Bispecific (EpCAM x CD3) | Fresenius Biotech (Catumaxomab legacy), Trion Pharma, Amgen, Next-gen Biotechs | Malignant Ascites, Solid Tumors, Carcinomas | Heterodimer Validation (Need Cross-reactive Abs against human/rat EpCAM domains) |
| Immunotoxin | Sesen Bio (VB4-845), Academic Consortia | Non-muscle Invasive Bladder Cancer, Solid Tumors | Binding Affinity under acidic conditions (Endosomal release simulation) |
| CAR-T | Academic Medical Centers, CAR-T Developers, Cell Therapy Innovators | Metastatic Colorectal Cancer, Refractory Solid Tumors | Stable Cell Line Generation (Need Lentivirus for high-expression target cells); Specificity Screening (Need strict purity controls) |